336 related articles for article (PubMed ID: 33827440)
1. Differentiation of small (≤ 3 cm) hepatocellular carcinomas from benign nodules in cirrhotic liver: the added additive value of MRI-based radiomics analysis to LI-RADS version 2018 algorithm.
Zhong X; Guan T; Tang D; Li J; Lu B; Cui S; Tang H
BMC Gastroenterol; 2021 Apr; 21(1):155. PubMed ID: 33827440
[TBL] [Abstract][Full Text] [Related]
2. Radiomics machine-learning signature for diagnosis of hepatocellular carcinoma in cirrhotic patients with indeterminate liver nodules.
Mokrane FZ; Lu L; Vavasseur A; Otal P; Peron JM; Luk L; Yang H; Ammari S; Saenger Y; Rousseau H; Zhao B; Schwartz LH; Dercle L
Eur Radiol; 2020 Jan; 30(1):558-570. PubMed ID: 31444598
[TBL] [Abstract][Full Text] [Related]
3. Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US.
Darnell A; Forner A; Rimola J; Reig M; García-Criado Á; Ayuso C; Bruix J
Radiology; 2015 Jun; 275(3):698-707. PubMed ID: 25658038
[TBL] [Abstract][Full Text] [Related]
4. Fat-containing hepatocellular carcinoma in patients with cirrhosis: proposal of a diagnostic modification regarding enhancement characteristics.
Delagnes A; Roux M; Vilgrain V; Guiu B; Laurent V; Sutter O; Bricault I; Trillaud H; Aubé C; Paisant A
Eur Radiol; 2024 Apr; 34(4):2283-2293. PubMed ID: 37816923
[TBL] [Abstract][Full Text] [Related]
5. New Arterial Phase Enhancing Nodules on MRI of Cirrhotic Liver: Risk of Progression to Hepatocellular Carcinoma and Implications for LI-RADS Classification.
Smereka P; Doshi AM; Lavelle LP; Shanbhogue K
AJR Am J Roentgenol; 2020 Aug; 215(2):382-389. PubMed ID: 32432909
[No Abstract] [Full Text] [Related]
6. Analysis of Lipiodol uptake in angiography and computed tomography for the diagnosis of malignant versus benign hepatocellular nodules in cirrhotic liver.
Langenbach MC; Vogl TJ; von den Driesch I; Kaltenbach B; Scholtz JE; Hammerstingl RM; Gruber-Rouh T
Eur Radiol; 2019 Dec; 29(12):6539-6549. PubMed ID: 31236701
[TBL] [Abstract][Full Text] [Related]
7. Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver.
Xu PJ; Yan FH; Wang JH; Shan Y; Ji Y; Chen CZ
J Comput Assist Tomogr; 2010 Jul; 34(4):506-12. PubMed ID: 20657216
[TBL] [Abstract][Full Text] [Related]
8. Man or machine? Prospective comparison of the version 2018 EASL, LI-RADS criteria and a radiomics model to diagnose hepatocellular carcinoma.
Jiang H; Liu X; Chen J; Wei Y; Lee JM; Cao L; Wu Y; Duan T; Li X; Ma L; Song B
Cancer Imaging; 2019 Dec; 19(1):84. PubMed ID: 31806050
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic efficacy of the Liver Imaging-Reporting and Data System (LI-RADS) with CT imaging in categorising small nodules (10-20 mm) detected in the cirrhotic liver at screening ultrasound.
Abd Alkhalik Basha M; Abd El Aziz El Sammak D; El Sammak AA
Clin Radiol; 2017 Oct; 72(10):901.e1-901.e11. PubMed ID: 28673446
[TBL] [Abstract][Full Text] [Related]
10. Radiomics model based on preoperative gadoxetic acid-enhanced MRI for predicting liver failure.
Zhu WS; Shi SY; Yang ZH; Song C; Shen J
World J Gastroenterol; 2020 Mar; 26(11):1208-1220. PubMed ID: 32231424
[TBL] [Abstract][Full Text] [Related]
11. Added Value of Quantitative Apparent Diffusion Coefficients for Identifying Small Hepatocellular Carcinoma from Benign Nodule Categorized as LI-RADS 3 and 4 in Cirrhosis.
Zhong X; Tang H; Guan T; Lu B; Zhang C; Tang D; Li J; Cui S
J Clin Transl Hepatol; 2022 Feb; 10(1):34-41. PubMed ID: 35233371
[TBL] [Abstract][Full Text] [Related]
12. Real-life assessment of standardized contrast-enhanced ultrasound (CEUS) and CEUS algorithms (CEUS LI-RADS®/ESCULAP) in hepatic nodules in cirrhotic patients-a prospective multicenter study.
Strobel D; Jung EM; Ziesch M; Praktiknjo M; Link A; Dietrich CF; Klinger C; Schultheiß M; Jesper D; Schellhaas B
Eur Radiol; 2021 Oct; 31(10):7614-7625. PubMed ID: 33855588
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.
Seo N; Kim MS; Park MS; Choi JY; Do RKG; Han K; Kim MJ
Eur Radiol; 2020 Jan; 30(1):261-271. PubMed ID: 31418085
[TBL] [Abstract][Full Text] [Related]
14. Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging.
De Gaetano AM; Catalano M; Pompili M; Marini MG; Rodríguez Carnero P; Gullì C; Infante A; Iezzi R; Ponziani FR; Cerrito L; Marrone G; Giuliante F; Ardito F; Rapaccini GL; Vecchio FM; Giraldi L; Manfredi R;
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7786-7801. PubMed ID: 31599447
[TBL] [Abstract][Full Text] [Related]
15. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
Lee MH; Kim SH; Park MJ; Park CK; Rhim H
AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients.
Darnell A; Rimola J; Belmonte E; Ripoll E; Garcia-Criado Á; Caparroz C; Díaz-González Á; Vilana R; Reig M; Ayuso C; Bruix J; Forner A
Eur Radiol; 2021 Jul; 31(7):4794-4803. PubMed ID: 33409789
[TBL] [Abstract][Full Text] [Related]
17. Comparison of LI-RADS with other non-invasive liver MRI criteria and radiological opinion for diagnosing hepatocellular carcinoma in cirrhotic livers using gadoxetic acid with histopathological explant correlation.
Clarke CGD; Albazaz R; Smith CR; Rowe I; Treanor D; Wyatt JI; Sheridan MB; Guthrie JA
Clin Radiol; 2021 May; 76(5):333-341. PubMed ID: 33461746
[TBL] [Abstract][Full Text] [Related]
18. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.
Terzi E; Iavarone M; Pompili M; Veronese L; Cabibbo G; Fraquelli M; Riccardi L; De Bonis L; Sangiovanni A; Leoni S; Zocco MA; Rossi S; Alessi N; Wilson SR; Piscaglia F;
J Hepatol; 2018 Mar; 68(3):485-492. PubMed ID: 29133247
[TBL] [Abstract][Full Text] [Related]
19. LI-RADS-CEUS - Proposal for a Contrast-Enhanced Ultrasound Algorithm for the Diagnosis of Hepatocellular Carcinoma in High-Risk Populations.
Schellhaas B; Wildner D; Pfeifer L; Goertz RS; Hagel A; Neurath MF; Strobel D
Ultraschall Med; 2016 Dec; 37(6):627-634. PubMed ID: 27486793
[No Abstract] [Full Text] [Related]
20. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
